重组完整抗体研究进展

Advances in the studies of recombinat intact immunoglobulins

重组分子抗体是一类潜在的治疗用药物 ,约占目前进入临床试验的生物制品类药物的三分之一 ,FDA批准上市的抗体药物有近十种 ,其中多数为重组的完整人源抗体 (包括人鼠嵌合抗体和人源化抗体 ) 。

Recombinant antibodies and their fragments now represent over 30% of all biological proteins undergoing clinical trials for diagnosis and therapy. FDA has approved about 10 antibody products for clinical use. Most of these therapeutic antibodies are intact immunoglobulins. In this review, the recent advances in the experimental studies on recombinant intact immunoglobulins are described.